Table II.
Unadjusted Analysis: Clinical Characteristics and Growth Rate
Clinical Characteristic | AAA Growth Rate without Clinical Characteristic (cm/yr) | Change in Growth Rate with Clinical Characteristic (cm/yr) | Clinical Characteristic*time p-value |
---|---|---|---|
Randomized Doxycycline Rx | 0.19 | 0.01 | 0.43 |
Diabetes | 0.21 | −0.06 | <0.0001 |
Female sex | 0.21 | −0.02 | 0.01 |
Smoking current | 0.19 | 0.05 | 0.0001 |
Smoking former | 0.19 | −0.02 | 0.66 |
COPD | 0.19 | 0.00 | 0.24 |
ARB therapy | 0.20 | −0.06 | <0.0001 |
Statin therapy | 0.22 | −0.03 | <0.0001 |
Beta blocker therapy | 0.20 | −0.01 | 0.22 |
BMI (per kg/m2) | −0.0019 | <0.01 |
Unadjusted associations of clinical characteristics and the AAA growth rate in the N-TA3CT. Mean growth rates as calculated by linear regression. P-values presented for each clinical characteristic are derived from a linear mixed effects model on AAA growth. BMI is treated as a continuous variable – the effect on the AAA growth is presented as a linear coefficient.